


# BioVendor

Research  
and Diagnostic Products



## HUMAN SIL – 2R ELISA

Product Data Sheet

Cat. No.: RBMS212/2R

For Research Use Only

## CONTENTS

---

1	INTENDED USE	3
2	SUMMARY	3
3	PRINCIPLES OF THE TEST	4
4	REAGENTS PROVIDED	5
5	STORAGE INSTRUCTIONS – ELISA KIT	5
6	SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS	6
7	MATERIALS REQUIRED BUT NOT PROVIDED	6
8	PRECAUTIONS FOR USE	7
9	PREPARATION OF REAGENTS	8
10	TEST PROTOCOL	10
11	CALCULATION OF RESULTS	12
12	LIMITATIONS	15
13	PERFORMANCE CHARACTERISTICS	15
14	REFERENCES	19
15	REAGENT PREPARATION SUMMARY	21
16	TEST PROTOCOL SUMMARY	22

»» This kit is manufactured by:  
BioVendor – Laboratorní medicína, a.s.

»» Use only the current version of Product Data Sheet enclosed with the kit!

## 1 INTENDED USE

---

The human sIL-2R ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human sIL-2R. The human sIL-2R ELISA is for research use only. Not for diagnostic or therapeutic procedures.

## 2 SUMMARY

---

Interleukin-2 (IL-2) has been described as a factor that promotes the growth and proliferation of human T-cells thus occupying a pivotal role in the generation of the immune response. This proliferation of T lymphocytes is triggered by the interaction of IL-2 with its specific cell surface receptor following T lymphocyte activation. The receptor for IL-2 is composed of at least three distinct polypeptide subunits, the IL-2R $\alpha$ , IL-2R $\beta$ , and the IL-2R $\gamma$  chains giving rise to a 55-65 kD membrane bound protein.

The genes encoding IL-2 and these three receptor subunits have been cloned and their complete primary structures have been deduced. Evidence has accumulated that suggests a critical role of IL-2R $\beta$  in IL-2 signal transduction. IL-2R coupled tyrosine kinases are believed to play a crucial role in that signal transduction.

In addition to the de-novo expression of IL-2R by activated peripheral blood T-cells, a released and fully soluble form of IL-2R (sIL-2R) has been detected. It was shown that sIL-2R is present *in vivo*, at low levels in the sera of healthy persons and at markedly elevated levels in various pathological conditions like neoplastic disorders. The structural, functional and molecular characteristics of sIL-2R have been extensively investigated. By virtue of its ability to bind IL-2, this soluble molecule plays a role in the regulation of the immune response. The detection and quantitation of sIL-2R provides clinicians with a useful and simple means of assessing immune function *in vivo* as part of the investigation, management and prognosis of a broad spectrum of human diseases.

### - hematologic malignancies (neoplasias):

Soluble IL-2R levels are significantly elevated in the sera of patients with adult T-cell leukemia, hairy cell leukemia, lymphocytic leukemia, Hodgkin's and Non-Hodgkin's lymphoma, liver, breast and lung cancer.

### - autoimmune or inflammatory diseases:

In patients with systemic lupus erythematosus, rheumatoid arthritis, progressive systemic sclerosis, polymyositis, Kawasaki disease, multiple sclerosis and Diabetes type I plasma concentrations of sIL-2 receptor are significantly elevated as compared to controls.

### - infectious diseases:

Both viral and mycobacterial infections lead to high levels of soluble IL-2R found in Hepatitis, HIV-1, infectious mononucleosis, measles, leprosy, tuberculosis as well as in malaria.

- transplantation or rejection:

sIL-2R turned out to be a very useful marker for monitoring of transplant recipients who show significant elevations of sIL-2R serum levels experiencing rejection episodes in kidney, lung, heart and liver transplantations.

- chronic renal failure or dialysis:

Impaired renal function elevates serum sIL-2R as this molecule is actively transported into the urine.

- skin:


sIL-2R is significantly elevated in patients with thermal injury.

- therapy:

Recombinant IL-2 as a cancer therapeutic can provoke release of sIL-2R.


### 3 PRINCIPLES OF THE TEST

An anti-human sIL-2R coating antibody is adsorbed onto microwells. Figure 1




Human sIL-2R present in the sample or standard binds to antibodies adsorbed to the microwells. A HRP-conjugated anti-human sIL-2R antibody is added and binds to human sIL-2R captured by the first antibody.

Figure 2  
First Incubation




Following incubation unbound HRP-conjugated anti-human sIL-2R is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

Figure 3  
Second Incubation



A coloured product is formed in proportion to the amount of human sIL-2R present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from 7 human sIL-2R standard dilutions and human sIL-2R concentration determined.

Figure 4



## 4 REAGENTS PROVIDED

- 1 aluminium pouch with a Antibody Coated Microtiter Strips with monoclonal antibody to human sIL-2R
- 1 vial (100 µl) HRP-Conjugate anti-human sIL-2R monoclonal antibody
- 2 vials human sIL-2R Standard lyophilized, 40 ng/ml upon reconstitution
- 1 vial (12 ml) Sample Diluent
- 1 vial (5 ml) Assay Buffer Concentrate 20x (PBS with 1% Tween 20 and 10% BSA)
- 1 bottle (50 ml) Wash Buffer Concentrate 20x (PBS with 1% Tween 20)
- 1 vial (15 ml) Substrate Solution (tetramethyl-benzidine)
- 1 vial (15 ml) Stop Solution (1M Phosphoric acid)
- 1 vial (0.4 ml) Blue-Dye
- 1 vial (0.4 ml) Green-Dye
- 2 Adhesive Films

## 5 STORAGE INSTRUCTIONS – ELISA KIT

Store kit reagents between 2° and 8°C. Immediately after use remaining reagents should be returned to cold storage (2° to 8°C). Expiry of the kit and reagents is stated on labels.

Expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, this reagent is not contaminated by the first handling.

## 6 SPECIMEN COLLECTION AND STORAGE INSTRUCTIONS

---

Cell culture supernatant, serum and plasma (EDTA, citrate, heparin) were tested with this assay. Other biological samples might be suitable for use in the assay. Remove serum or plasma from the clot or cells as soon as possible after clotting and separation.

Pay attention to a possible “Hook Effect” due to high sample concentrations (see chapter 11). Samples containing a visible precipitate must be clarified prior to use in the assay. Do not use grossly hemolyzed or lipemic specimens.

Samples should be aliquoted and must be stored frozen at -20°C to avoid loss of bioactive human sIL-2R. If samples are to be run within 24 hours, they may be stored at 2° to 8°C (for sample stability refer to 13.5).

Avoid repeated freeze-thaw cycles. Prior to assay, the frozen sample should be brought to room temperature slowly and mixed gently.

## 7 MATERIALS REQUIRED BUT NOT PROVIDED

---

- 5 ml and 10 ml graduated pipettes
- 5 µl to 1000 µl adjustable single channel micropipettes with disposable tips
- 50 µl to 300 µl adjustable multichannel micropipette with disposable tips
- Multichannel micropipette reservoir
- Beakers, flasks, cylinders necessary for preparation of reagents
- Device for delivery of wash solution (multichannel wash bottle or automatic wash system)
- Microwell strip reader capable of reading at 450 nm (620 nm as optional reference wave length)
- Glass-distilled or deionized water
- Statistical calculator with program to perform regression analysis

## 8 PRECAUTIONS FOR USE

---

- All chemicals should be considered as potentially hazardous. We therefore recommend that this product is handled only by those persons who have been trained in laboratory techniques and that it is used in accordance with the principles of good laboratory practice. Wear suitable protective clothing such as laboratory overalls, safety glasses and gloves. Care should be taken to avoid contact with skin or eyes. In the case of contact with skin or eyes wash immediately with water. See material safety data sheet(s) and/or safety statement(s) for specific advice.
- Reagents are intended for research use only and are not for use in diagnostic or therapeutic procedures.
- Do not mix or substitute reagents with those from other lots or other sources.
- Do not use kit reagents beyond expiration date on label.
- Do not expose kit reagents to strong light during storage or incubation.
- Do not pipette by mouth.
- Do not eat or smoke in areas where kit reagents or samples are handled.
- Avoid contact of skin or mucous membranes with kit reagents or specimens.
- Rubber or disposable latex gloves should be worn while handling kit reagents or specimens.
- Avoid contact of substrate solution with oxidizing agents and metal.
- Avoid splashing or generation of aerosols.
- In order to avoid microbial contamination or cross-contamination of reagents or specimens which may invalidate the test use disposable pipette tips and/or pipettes.
- Use clean, dedicated reagent trays for dispensing the conjugate and substrate reagent.
- Exposure to acid inactivates the conjugate.
- Glass-distilled water or deionized water must be used for reagent preparation.
- Substrate solution must be at room temperature prior to use.
- Decontaminate and dispose specimens and all potentially contaminated materials as they could contain infectious agents. The preferred method of decontamination is autoclaving for a minimum of 1 hour at 121.5°C.
- Liquid wastes not containing acid and neutralized waste may be mixed with sodium hypochlorite in volumes such that the final mixture contains 1.0% sodium hypochlorite. Allow 30 minutes for effective decontamination. Liquid waste containing acid must be neutralized prior to the addition of sodium hypochlorite.

## 9 PREPARATION OF REAGENTS

Buffer Concentrates should be brought to room temperature and should be diluted before starting the test procedure.

If crystals have formed in the Buffer Concentrates, warm them gently until they have completely dissolved.

### 9.1 Wash Buffer (1x)

Pour entire contents (50 ml) of the Wash Buffer Concentrate (20x) into a clean 1000 ml graduated cylinder. Bring to final volume of 1000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4.

Transfer to a clean wash bottle and store at 2° to 25°C. Please note that Wash Buffer (1x) is stable for 30 days.

Wash Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Wash Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

### 9.2 Assay Buffer (1x)

Pour the entire contents (5 ml) of the Assay Buffer Concentrate (20x) into a clean 100 ml graduated cylinder. Bring to final volume of 100 ml with distilled water. Mix gently to avoid foaming.

Store at 2° to 8°C. Please note that the Assay Buffer (1x) is stable for 30 days.

Assay Buffer (1x) may also be prepared as needed according to the following table:

Number of Strips	Assay Buffer Concentrate (20x) (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

### 9.3 HRP-Conjugate

Please note that the HRP-Conjugate should be used within 30 minutes after dilution.

Make a 1:100 dilution of the concentrated HRP-Conjugate solution with Assay Buffer (1x) in a clean plastic tube as needed according to the following table:

Number of Strips	HRP-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94



## 9.4 Human sIL-2R Standard

Reconstitute human sIL-2R standard by addition of distilled water.

Reconstitution volume is stated in the Quality Control Sheet. Swirl or mix gently to insure complete and homogeneous solubilization (concentration of reconstituted standard = 40 ng/ml). Allow the standard to reconstitute for 10-30 minutes. Mix well prior to making dilutions.

After usage remaining standard cannot be stored and has to be discarded.

Standard dilutions can be prepared directly on the microwell plate (see 10.c) or alternatively in tubes (see 9.4.1).

### 9.4.1 External Standard Dilution

Label 7 tubes, one for each standard point.

S1, S2, S3, S4, S5, S6, S7


Then prepare 1:2 serial dilutions for the standard curve as follows:

Pipette 225  $\mu$ l of Sample Diluent into each tube.

Pipette 225  $\mu$ l of reconstituted standard (concentration = 40 ng/ml) into the first tube, labelled S1, and mix (concentration of standard 1 = 20 ng/ml). Pipette 225  $\mu$ l of this dilution into the second tube, labelled S2, and mix thoroughly before the next transfer. Repeat serial dilutions 5 more times thus creating the points of the standard curve (see Figure 5).

Sample Diluent serves as blank.

Figure 5



## 9.5 Addition of Colour-giving Reagents: Blue-Dye, Green-Dye

In order to help our customers to avoid any mistakes in pipetting the Bender MedSystems ELISAs, Bender MedSystems offers a tool that helps to monitor the addition of even very small volumes of a solution to the reaction well by giving distinctive colours to each step of the ELISA procedure.

This procedure is optional, does not in any way interfere with the test results, and is designed to help the customer with the performance of the test, but can also be omitted, just following the instruction booklet.

Alternatively, the dye solutions from the stocks provided (*Blue-Dye*, *Green-Dye*) can be added to the reagents according to the following guidelines:

1. Diluent: Before standard and sample dilution add the *Blue-Dye* at a dilution of 1:250 (see table below) to the appropriate diluent (1x) according to the test protocol. After addition of *Blue-Dye*, proceed according to the instruction booklet.

5 ml Sample Diluent	20 µl <i>Blue-Dye</i>
12 ml Sample Diluent	48 µl <i>Blue-Dye</i>
50 ml Sample Diluent	200 µl <i>Blue-Dye</i>

2. HRP-Conjugate: Before dilution of the concentrated HRP-Conjugate add the *Green-Dye* at a dilution of 1:100 (see table below) to the Assay Buffer (1x) used for the final conjugate dilution. Proceed after addition of *Green-Dye* according to the instruction booklet: Preparation of HRP-Conjugate.


3 ml Assay Buffer (1x)	30 µl <i>Green-Dye</i>
6 ml Assay Buffer (1x)	60 µl <i>Green-Dye</i>

## 10 TEST PROTOCOL

- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Each sample, standard, blank and optional control sample should be assayed in duplicate. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2°- 8°C sealed tightly.
- Wash the microwell strips twice with approximately 400 µl Wash Buffer per well with thorough aspiration of microwell contents between washes. Allow the Wash Buffer to sit in the wells for about 10 – 15 seconds before aspiration. Take care not to scratch the surface of the microwells. After the last wash step, empty wells and tap microwell strips on absorbent pad or paper towel to remove excess Wash Buffer. Use the microwell strips immediately after washing. Alternatively microwell strips can be placed upside down on a wet absorbent paper for not longer than 15 minutes. Do not allow wells to dry.

- c. Standard dilution on the microwell plate (Alternatively the standard dilution can be prepared in tubes - see 9.4.1): Add 100 µl of Sample Diluent in duplicate to all standard wells. Pipette 100 µl of prepared standard (see Preparation of Standard 9.4, concentration = 40.00 ng/ml) in duplicate into well A1 and A2 (see Table 1). Mix the contents of wells A1 and A2 by repeated aspiration and ejection (concentration of standard 1, S1 = 20.00 ng/ml), and transfer 100 µl to wells B1 and B2, respectively (see Figure 6). Take care not to scratch the inner surface of the microwells. Continue this procedure 5 times, creating two rows of human sIL-2R standard dilutions ranging from 20.00 to 0.31 ng/ml. Discard 100 µl of the contents from the last microwells (G1, G2) used.

Figure 6



In case of an external standard dilution (see 9.4.1), pipette 100 µl of these standard dilutions (S1 - S7) in the standard wells according to Table 1.

Table 1

Table depicting an example of the arrangement of blanks, standards and samples in the microwell strips:

	1	2	3	4
A	Standard 1 (20.00 ng/ml)	Standard 1 (20.00 ng/ml)	Sample 1	Sample 1
B	Standard 2 (10.00 ng/ml)	Standard 2 (10.00 ng/ml)	Sample 2	Sample 2
C	Standard 3 (5.00 ng/ml)	Standard 3 (5.00 ng/ml)	Sample 3	Sample 3
D	Standard 4 (2.50 ng/ml)	Standard 4 (2.50 ng/ml)	Sample 4	Sample 4
E	Standard 5 (1.25 ng/ml)	Standard 5 (1.25 ng/ml)	Sample 5	Sample 5
F	Standard 6 (0.63 ng/ml)	Standard 6 (0.63 ng/ml)	Sample 6	Sample 6
G	Standard 7 (0.31 ng/ml)	Standard 7 (0.31 ng/ml)	Sample 7	Sample 7
H	Blank	Blank	Sample 8	Sample 8

- d. Add 100 µl of Sample Diluent in duplicate to the blank wells.
- e. Add 50 µl of Sample Diluent to the sample wells.
- f. Add 50 µl of each sample in duplicate to the sample wells.
- g. Prepare HRP-Conjugate (see Preparation of HRP-Conjugate 9.3).
- h. Add 50 µl of HRP-Conjugate to all wells.
- i. Cover with an adhesive film and incubate at room temperature (18 to 25°C) for 3 hours, if available on a microplate shaker set at 100 rpm.
- j. Remove adhesive film and empty wells. Wash microwell strips 3 times according to point b. of the test protocol. Proceed immediately to the next step.
- k. Pipette 100 µl of TMB Substrate Solution to all wells.
- l. Incubate the microwell strips at room temperature (18° to 25°C) for about 10 min. Avoid direct exposure to intense light.

The colour development on the plate should be monitored and the substrate reaction stopped (see next point of this protocol) before positive wells are no longer properly recordable. Determination of the ideal time period for colour development has to be done individually for each assay.

It is recommended to add the stop solution when the highest standard has developed a dark blue colour. Alternatively the colour development can be monitored by the ELISA reader at 620 nm. The substrate reaction should be stopped as soon as Standard 1 has reached an OD of 0.90 – 0.95.

- m. Stop the enzyme reaction by quickly pipetting 100 µl of Stop Solution into each well. It is important that the Stop Solution is spread quickly and uniformly throughout the microwells to completely inactivate the enzyme. Results must be read immediately after the Stop Solution is added or within one hour if the microwell strips are stored at 2 - 8°C in the dark.
- n. Read absorbance of each microwell on a spectro-photometer using 450 nm as the primary wave length (optionally 620 nm as the reference wave length; 610 nm to 650 nm is acceptable). Blank the plate reader according to the manufacturer's instructions by using the blank wells. Determine the absorbance of both the samples and the standards.

**Note:** In case of incubation without shaking the obtained O.D. values may be lower than indicated below. Nevertheless the results are still valid.

## 11 CALCULATION OF RESULTS

---

- Calculate the average absorbance values for each set of duplicate standards and samples. Duplicates should be within 20 per cent of the mean value.
- Create a standard curve by plotting the mean absorbance for each standard concentration on the ordinate against the human sIL-2R concentration on the abscissa. Draw a best fit curve through the points of the graph (a 5-parameter curve fit is recommended).
- To determine the concentration of circulating human sIL-2R for each sample, first find the mean absorbance value on the ordinate and extend a horizontal line to the standard curve.

At the point of intersection, extend a vertical line to the abscissa and read the corresponding human sIL-2R concentration.

- If instructions in this protocol have been followed samples have been diluted 1:2 (50  $\mu$ l sample + 50  $\mu$ l Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).
- Calculation of samples with a concentration exceeding standard 1 will result in incorrect, low human sIL-2R levels (Hook Effect). Such samples require further external predilution according to expected human sIL-2R values with Sample Diluent in order to precisely quantitate the actual human sIL-2R level.
- It is suggested that each testing facility establishes a control sample of known human sIL-2R concentration and runs this additional control with each assay. If the values obtained are not within the expected range of the control, the assay results may be invalid.
- A representative standard curve is shown in Figure 7. This curve cannot be used to derive test results. Each laboratory must prepare a standard curve for each group of microwell strips assayed.

Figure 7

Representative standard curve for human sIL-2R ELISA. Human sIL-2R was diluted in serial 2-fold steps in Sample Diluent. Do not use this standard curve to derive test results. A standard curve must be run for each group of microwell strips assayed.




Table 2

Typical data using the human sIL-2R ELISA

Measuring wavelength: 450 nm

Reference wavelength: 620 nm

Standard	Human sIL-2R Concentration (ng/ml)	O.D. at 450 nm	Mean O.D. at 450 nm	C.V. (%)
1	20.00	2.239 2.193	2.216	3.25
2	10.00	1.366 1.354	1.360	0.85
3	5.00	0.710 0.747	0.729	2.62
4	2.50	0.403 0.410	0.407	0.49
5	1.25	0.204 0.219	0.212	1.06
6	0.63	0.120 0.122	0.121	0.14
7	0.31	0.071 0.074	0.073	0.21
Blank	0	0.010 0.012	0.011	0.14

The OD values of the standard curve may vary according to the conditions of assay performance (e.g. operator, pipetting technique, washing technique or temperature effects). Furthermore shelf life of the kit may affect enzymatic activity and thus colour intensity. Values measured are still valid.

## 12 LIMITATIONS

---

- Since exact conditions may vary from assay to assay, a standard curve must be established for every run.
- Bacterial or fungal contamination of either screen samples or reagents or cross-contamination between reagents may cause erroneous results.
- Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.
- Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Empty wells completely before dispensing fresh wash solution, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.
- The use of radioimmunotherapy has significantly increased the number of patients with human anti-mouse IgG antibodies (HAMA). HAMA may interfere with assays utilizing murine monoclonal antibodies leading to both false positive and false negative results. Serum samples containing antibodies to murine immunoglobulins can still be analysed in such assays when murine immunoglobulins (serum, ascitic fluid, or monoclonal antibodies of irrelevant specificity) are added to the sample.

## 13 PERFORMANCE CHARACTERISTICS

---

### 13.1 Sensitivity

The limit of detection of human sIL-2R defined as the analyte concentration resulting in an absorbance significantly higher than that of the dilution medium (mean plus 2 standard deviations) was determined to be 0.27 ng/ml (mean of 6 independent assays).

### 13.2 Reproducibility

#### 13.2.1 Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 6 serum samples containing different concentrations of human sIL-2R. 2 standard curves were run on each plate. Data below show the mean human sIL-2R concentration and the coefficient of variation for each sample (see Table 3). The calculated overall intra-assay coefficient of variation was 7.2%.

Table 3

The mean human sIL-2R concentration and the coefficient of variation for each sample

Sample	Experiment	Mean Human sIL-2R Concentration (ng/ml)	Coefficient of Variation (%)
1	1	2.60	11
	2	2.53	7
	3	2.01	3
2	1	1.47	10
	2	1.54	7
	3	1.32	5
3	1	1.47	9
	2	1.56	7
	3	1.30	9
4	1	1.72	2
	2	1.80	7
	3	1.64	7
5	1	1.43	8
	2	1.52	11
	3	1.33	4
6	1	3.05	10
	2	3.42	5
	3	2.67	4

### 13.2.2 Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 6 serum samples containing different concentrations of human sIL-2R. 2 standard curves were run on each plate. Data below show the mean human sIL-2R concentration and the coefficient of variation calculated on 18 determinations of each sample (see Table 4). The calculated overall inter-assay coefficient of variation was 9.8%.

Table 4

The mean human sIL-2R concentration and the coefficient of variation of each sample

Sample	Mean Human sIL-2R Concentration (ng/ml)	Coefficient of Variation (%)
1	2.381	13.6
2	1.440	8.1
3	1.443	9.1
4	1.803	9.2
5	1.430	6.5
6	3.048	12.3



### 13.3 Spiking Recovery

The spiking recovery was evaluated by spiking 4 levels of human sIL-2R into different pooled normal human serum samples. Recoveries were determined in 3 independent experiments with 4 replicates each. The amount of endogenous human sIL-2R in unspiked serum was subtracted from the spike values.

The overall mean recovery was 75%.

### 13.4 Dilution Linearity

4 serum samples with different levels of human sIL-2R were analysed at serial 2 fold dilutions with 4 replicates each.

The recovery ranged from 77% to 107% with an overall recovery of 86% (see Table 5).

Table 5

Sample	Dilution	Expected Human sIL-2R Concentration (ng/ml)	Observed Human sIL-2R Concentration (ng/ml)	Recovery of Expected Human sIL-2R Concentration (%)
1	1:2	--	1.27	--
	1:4	6.37	5.92	93
	1:8	3.18	2.58	81
	1:16	1.59	1.28	81
2	1:2	--	17.0	--
	1:4	8.50	9.08	107
	1:8	4.25	3.83	90
	1:16	2.13	1.86	87
3	1:2	--	18.6	--
	1:4	9.30	8.35	90
	1:8	4.65	3.69	79
	1:16	2.33	1.78	77
4	1:2	--	16.72	--
	1:4	8.36	6.79	81
	1:8	4.18	3.49	83
	1:16	2.09	1.84	88

### 13.5 Sample Stability

#### 13.5.1 Freeze-Thaw Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C and thawed 5 times, and the human sIL-2R levels determined. There was no significant loss of human sIL-2R immunoreactivity detected by freezing and thawing.

#### 13.5.2 Storage Stability

Aliquots of serum samples (spiked or unspiked) were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the human sIL-2R level determined after 24, 48 and 96 h. There was no significant loss of human sIL-2R immunoreactivity detected during storage under above conditions.

### 13.6 Specificity

The interference of circulating factors of the immune system was evaluated by spiking these proteins at physiologically relevant concentrations into a human IL-2R positive serum. There was no crossreactivity detected.

### 13.7 Expected Values

Panels of 40 serum as well as EDTA, citrate and heparin plasma samples from randomly selected apparently healthy donors (males and females) were tested for human IL-2R.

The levels measured may vary with the sample collection used.

For detected human IL-2R levels see Table 6.

Table 6

Sample Matrix	Number of Samples Evaluated	Range (ng/ml)	Mean (ng/ml)	Standard Deviation (ng/ml)
Serum	40	1.9 – 13.1	4.7	2.6
Plasma (EDTA)	40	0.9 – 8.1	2.4	1.3
Plasma (Citrate)	40	1.8 - 7.8	3.8	1.65
Plasma (Heparin)	40	2.12 – 8.0	4.0	1.7

## 14 REFERENCES

---

- 1) Brown A. E., K. T. Rieder, and H. K. Webster. (1989). Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. *Am. Rev. Respir. Dis.* 139, 1036-1038.
- 2) Chilosi M., G. Semenzato, and F. Vinante. (1989). Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic and phenotypic features. *Am. J. Clin. Pathol.* 92, 186-191.
- 3) Chu C. M., and Y. F. Liaw. (1989). Serum levels of soluble Tac peptide in acute and chronic hepatitis B virus infection. *Clin. Immunol. Immunopathol.* 53, 52-58.
- 4) Cornaby A., M. A. Simpson, R. V. Rice, R. A. Dempsey, P. N. Madras, and A. P. Monaco. (1988). Interleukin-2 production in plasma, urine and plasma interleukin-2 receptor levels and urine cytology as a means of monitoring renal allograft recipients. *Transplantation Proc.* 20, 108-110.
- 5) Cosman D., D. P. Ceretti, A. Larsen, L. Park, C. March, S. Dower, S. Gills, and D. Urdall. (1984). Cloning, sequencing and expression of human interleukin-2 receptor. *Nature* 312, 768-771.
- 6) Deloron P., J. P. Lepers, and P. Coulanges. (1989). Evolution of the levels of soluble interleukin-2 receptors during *Plasmodium falciparum* and *P. vivax* malaria. *J. Clin. Microbiol.* 27, 1887-1889.
- 7) Giordano C., A. Galluzzo, and A. Marco. (1988). Increased soluble interleukin-2 levels in the sera of type I diabetic patients. *Diabetes*
- 8) Greenberg S. J., L. Marcon, B. J. Hirevitz, T. A. Waldmann, and D. L. Nelson. (1988). Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. *N. Engl. J. Med.* 319, 1019-1020.
- 9) Griffin D. E. B. J. Ward, E. Jauregui, R. T. Johnson, and A. Vaisberg. (1989). Immune activation in measles. *N. Engl. J. Med.*
- 10) Hatakeyama M., M. Tsudo, S. Minamoto, T. Kono, T. Doi, T. Miyata, M. Miyasaka, and T. Taniguchi. (1989). Interleukin-2 receptor  $\alpha$  chain gene: Generation of three receptor forms by cloned human  $\alpha$  and  $\beta$  chain cDNAs. *Science* 244, 551-556.
- 11) Keshavjee S. H., D. I. McRitchie, L. A. Rubin, J. Maurer, M. Girotti, and G. A. Patterson. (1989). The role of soluble interleukin-2 receptor levels in the diagnosis of rejection and infection in lung transplant recipients. *Clin. Inv. Med.* 12, B101.
- 12) Keystone E. C., K. M. Snow, C. Bombardier, C. H. Chang, D. L. Nelson, and L. A. Rubin. (1988). Elevated soluble IL-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. *Arthritis Rheum.* 31, 844-849.
- 13) Lang B. A., E. D. Silverman, R. M. Laxer, V. Rose, D. L. Nelson, and L. A. Rubin. (1990). Serum soluble IL-2 receptor levels in Kawasaki disease. *J. Paeds.* 116, 592-596.
- 14) Lee G. L., M. Y. Chen, C. Y. Chuang, and C. Y. Chen. (1988). Serum interleukin-2 receptor in systemic lupus erythematosus and rheumatoid arthritis. *Chung Hua Min Jue Wei Sheng Wu Chi Mien I Hsueh Tsa Chih* 21, 16-22.

- 15) Lotze M. T., M. C. Custer, S. O. Sharrow, L. A. Rubin, D. L. Nelson, and S. A. Rosenberg. (1987). In vivo administration of purified human interleukin-2 to patients with cancer development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration *Cancer Res.* 47, 2188-2195.
- 16) Minami Y., T. Kono, T. Miyazaki, and T. Taniguchi. (1993). The IL-2 receptor complex: Its structure, function and target genes. *Annu. Rev. Immunol.* 11, 245-267.
- 17) Morgan R. A., F. W. Ruscetti, and R. C. Gallo. (1976). Selective in vitro growth of T lymphocytes. *Science* 193, 1007-1008.
- 18) Motoi T., T. Uchiyama, T. Hori, K. Itoh, H. Uchino, and R. Ueda. (1989). Elevated serum soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. *Blood* 74, 1052-1057.
- 19) Nelson D. L., D. K. Wagner, L. Marcon, et al. (1987). An analysis of soluble IL-2 receptors in human neoplastic disorders. In: Albertini A. Lentant C. Poeletti R. eds. *Biotechnology in Clinical Medicine*, New York: Raven Press, 277-286.
- 20) Peacocke M., M. L. McLaughlin, L. A. Rubin, and D. L. Nelson. (1986). Elevated serum levels of IL-2 receptors are present in patients maintained on chronic hemodialysis (Abstract). *Clin. Res.*
- 21) Perkins J. D., D. L. Nelson, J. Rakela, P. M. Grambsch, and R. A. Krom. (1989). Soluble interleukin-2 receptor level in liver allograft recipients: an indicator of rejection. *Transplantation* 47, 77-81.
- 22) Peter J. B., M. S. Agopian, P. J. Clements, N. S. Telian, and D. E. Furst. (1989). Elevated serum levels of interleukin-2 receptor and IL-2 in diffuse and limited scleroderma. *Arthritis Rheum.* 32, 77.
- 23) Pizzolo G., M. Chilosi, and G. Semenzato. (1987). The soluble interleukin-2 receptor in haematological disorders. *Br. J. Haematol.*
- 24) Pizzolo G., M. Chilosi, and F. Vinante. (1987). Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. *Br. J. Cancer* 55, 427-428.
- 25) Prince H. E., S. Kleinman, and A. E. Williams. (1988). Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. *J. Immunol.* 140, 1139-1141.
- 26) Rovelli F., P. Lissoni, and S. Crispino. (1988). Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. *Tumori.* 74, 633-637.
- 27) Rubin L. A., C. C. Kurman, and M. E. Fritz. (1985). Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. *J. Immunol.* 135, 3172-3177.
- 28) Siegel J. P., M. Sharon, P. L. Smith, and W. J. Leonard. (1987). The IL-2 receptor  $\alpha$  chain (p70): Role in mediating signals for LAK, NK and proliferative activities. *Science* 238, 75-78.
- 29) Smith K. A. (1988). Interleukin-2: inception, impact and implications. *Science* 240, 1169-1176.
- 30) Steis R. G., L. Marcon, and J. Clark. (1988). Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. *Blood* 71, 1304-1309.

- 31) Southern J. T. (1986). A comparison of sIL-2R levels and endomyocardial biopsy grades in the monitoring of cardiac allograft rejection. *J. Heart Transpl.* 5, 370.
- 32) Takamatsu T., N. Tasuda, T. Ohno, T. Kanoh, H. Uchino, and A. Fujisawa. (1988). Soluble interleukin-2 receptors in the serum of patients with chronic renal failure. *Tohoku J. Exp. Med.* 155, 434-
- 33) Takashita T., H. Asao, K. Ohrani, N. Ishii, S. Kumaki, N. Tanaka, H. Munakata, M. Nakamura, and K. Sugamura. (1992). Cloning of the  $\alpha$ -chain of the human IL-2 receptor. *Science* 257, 379-382.
- 34) Teodorczyk-Injeyan J. A., G. B. Sparkes, G. B. Mills, R. E. Falk, and W. J. Peters. (1989). Increase of serum interleukin-2 receptor in thermally injured patients. *Clin. Immunol. Immunopathol* 51, 205-
- 35) Tung S. K., E. Umland, and P. Matziner. (1987). Soluble serum IL-2 receptor levels in leprosy patients. *Clin. Exp. Immunol.* 68, 10-
- 36) Turner B., U. Rapp, H. App, M. Greene, K. Dosbashi, and J. Reed. (1991). Interleukin-2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in T-cell line. *PNAS* 88, 1227-1231.
- 37) Yasuda N., P. K. Lai, and S. H. Ip. (1988). Soluble IL-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. *Blood* 71, 1021-1026.
- 38) Wolf R. E., and B. A. Baethge. (1989). Cytokines and interleukin-2 receptors in polymyositis. *Arthritis Rheum.* 32, 31.

## 15 REAGENT PREPARATION SUMMARY

### 15.1 Wash Buffer (1x)

Add Wash Buffer Concentrate 20x (50 ml) to 950 ml distilled water.

Number of Strips	Wash Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	25	475
1 - 12	50	950

### 15.2 Assay Buffer (1x)

Add Assay Buffer Concentrate 20x (5 ml) to 95 ml distilled water.

Number of Strips	Assay Buffer Concentrate (ml)	Distilled Water (ml)
1 - 6	2.5	47.5
1 - 12	5.0	95.0

### 15.3 HRP-Conjugate

Make a 1:100 dilution of HRP-Conjugate in Assay Buffer (1x):

Number of Strips	HRP-Conjugate (ml)	Assay Buffer (1x) (ml)
1 - 6	0.03	2.97
1 - 12	0.06	5.94

### 15.4 Human sIL-2R Standard

Reconstitute lyophilized human sIL-2R standard with distilled water. (Reconstitution volume is stated in the Quality Control Sheet.)


## 16 TEST PROTOCOL SUMMARY

1. Determine the number of microwell strips required.
2. Wash microwell strips twice with Wash Buffer.
3. Standard dilution on the microwell plate: Add 100 µl Sample Diluent, in duplicate, to all standard wells. Pipette 100 µl prepared standard into the first wells and create standard dilutions by transferring 100 µl from well to well. Discard 100 µl from the last wells. Alternatively external standard dilution in tubes (see 9.4.1): Pipette 100 µl of these standard dilutions in the microwell strips.
4. Add 100 µl Sample Diluent, in duplicate, to the blank wells.
5. Add 50 µl Sample Diluent to sample wells.
6. Add 50 µl sample in duplicate, to designated sample wells.
7. Prepare HRP-Conjugate.
8. Add 50 µl HRP-Conjugate to all wells.
9. Cover microwell strips and incubate 3 hours at room temperature (18° to 25°C).
10. Empty and wash microwell strips 3 times with Wash Buffer.
11. Add 100 µl of TMB Substrate Solution to all wells.
12. Incubate the microwell strips for about 10 minutes at room temperature (18° to 25°C).
13. Add 100 µl Stop Solution to all wells.
14. Blank microwell reader and measure colour intensity at 450 nm.

Note: If instructions in this protocol have been followed samples have been diluted 1:2 (50 µl sample + 50 µl Sample Diluent), the concentration read from the standard curve must be multiplied by the dilution factor (x 2).

NOTES





<b>HEADQUARTERS:</b> BioVendor Laboratorní medicína, a.s.	CTPark Modrice Evropska 873	664 42 Modrice CZECH REPUBLIC	Phone: +420-549-124-185 Fax: +420-549-211-460	E-mail: info@biovendor.com Web: www.biovendor.com
EUROPEAN UNION: BioVendor GmbH	Im Neuenheimer Feld 583	D-69120 Heidelberg GERMANY	Phone: +49-6221-433-9100 Fax: +49-6221-433-9111	E-mail: infoEU@biovendor.com
USA, CANADA AND MEXICO: BioVendor LLC	1463 Sand Hill Road Suite 227	Candler, NC 28715 USA	Phone: +1-828-670-7807 +1-800-404-7807 Fax: +1-828-670-7809	E-mail: infoUSA@biovendor.com
CHINA - Hong Kong Office: BioVendor Laboratories Ltd	Room 4008 Hong Kong Plaza, No.188	Connaught Road West Hong Kong, CHINA	Phone: +852-2803-0523 Fax: +852-2803-0525	E-mail: infoHK@biovendor.com
CHINA – Mainland Office: BioVendor Laboratories Ltd	Room 2405 YiYa Tower TianYu Garden, No.150	Lihe Zhong Road Guang Zhou, CHINA	Phone: +86-20-8706-3029 Fax: +86-20-8706-3016	E-mail: infoCN@biovendor.com